SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system.
Benedetta Maria BonoraEmanuel RaschiAngelo AvogaroGian Poalo FadiniPublished in: Cardiovascular diabetology (2021)
In a large pharmacovigilance database, AF was robustly and consistently reported more frequently for diabetes medications other than SGLT2i. This finding complements available evidence from trials supporting a protective role of SGLT2i against the occurrence of AF.
Keyphrases
- atrial fibrillation
- adverse drug
- drug administration
- left atrial
- catheter ablation
- oral anticoagulants
- type diabetes
- direct oral anticoagulants
- left atrial appendage
- cardiovascular disease
- heart failure
- percutaneous coronary intervention
- risk assessment
- emergency department
- glycemic control
- electronic health record
- drug induced
- skeletal muscle
- acute coronary syndrome
- metabolic syndrome
- adipose tissue
- weight loss
- coronary artery disease
- insulin resistance